| Product Code: ETC13129897 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Non-Alcoholic Steatohepatitis Treatment Market was valued at USD 2.6 Billion in 2024 and is expected to reach USD 6.1 Billion by 2031, growing at a compound annual growth rate of 12.90% during the forecast period (2025-2031).
The Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market is witnessing significant growth due to the rising prevalence of obesity and related liver conditions, increasing awareness about NASH, and the development of novel therapeutic options. The market is characterized by a growing pipeline of potential NASH treatments, including pharmaceuticals, lifestyle interventions, and surgical procedures. Key players in the market are investing in research and development to bring innovative therapies to the market, aiming to address the unmet medical needs of NASH patients globally. The market is also driven by collaborations between pharmaceutical companies and research institutions to accelerate drug development and improve treatment outcomes. With the increasing burden of NASH on healthcare systems worldwide, the market is expected to expand further in the coming years.
The Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market is experiencing significant growth due to the rising prevalence of NASH, driven by factors such as sedentary lifestyles and unhealthy dietary habits. The market is witnessing a shift towards the development of innovative treatment options, including novel drug therapies and combination therapies. With several pharmaceutical companies investing in research and development activities to address the unmet medical needs in NASH treatment, there are promising opportunities for market expansion. Additionally, collaborations between industry players and research institutions are on the rise, leading to advancements in diagnostic tools and personalized treatment approaches. The market is also witnessing a growing focus on patient education and awareness initiatives to improve early diagnosis and disease management, presenting avenues for market growth and development.
One of the main challenges faced in the Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market is the lack of approved drugs specifically targeting NASH. This has led to limited treatment options for patients, resulting in a significant unmet medical need. Additionally, the complex nature of NASH, which involves a combination of liver inflammation, fibrosis, and fatty liver disease, makes it difficult to develop effective therapies that can address all aspects of the disease. Regulatory hurdles and the high cost of conducting clinical trials for NASH treatments further compound the challenges in this market. As a result, pharmaceutical companies are investing heavily in research and development efforts to bring novel and effective treatments to market for this growing health concern.
The Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market is primarily being driven by the increasing prevalence of obesity and metabolic disorders, which are major risk factors for NASH development. Additionally, the rising awareness about the disease among both healthcare professionals and patients is leading to early diagnosis and treatment initiation. The introduction of novel therapies and drug pipelines targeting NASH is also propelling market growth, as pharmaceutical companies invest in research and development to address the unmet medical needs in this area. Furthermore, the growing burden of liver diseases worldwide, coupled with the escalating healthcare expenditure and supportive government initiatives, are further fueling the demand for NASH treatments and driving market expansion.
Government policies related to the Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market focus on improving awareness, prevention, and treatment strategies for NASH. These policies often emphasize the importance of promoting healthy lifestyles, increasing screening and diagnostic capabilities, and supporting research and development efforts for innovative treatments. Governments also aim to regulate the pharmaceutical industry to ensure safe and effective NASH treatments are available to patients. Additionally, there is a growing emphasis on healthcare cost containment and reimbursement policies to make NASH treatments more accessible and affordable to patients. Overall, government policies in the Global NASH Treatment Market aim to address the rising prevalence of NASH and its associated healthcare burden through comprehensive strategies that prioritize public health and patient outcomes.
The Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market is projected to witness significant growth in the coming years, driven by the rising prevalence of obesity and related metabolic disorders worldwide. Increasing awareness about NASH, advancements in diagnostic techniques, and the development of novel treatment options are expected to fuel market expansion. Additionally, collaborations between pharmaceutical companies and research institutions for the development of effective therapies and the growing pipeline of promising NASH drugs are likely to contribute to market growth. However, challenges such as the high cost of treatment, stringent regulatory requirements, and the lack of definitive diagnostic tools may hinder the market`s progression. Overall, the Global NASH Treatment Market is anticipated to experience steady growth as efforts intensify to address the unmet medical needs of NASH patients.
In the Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, various regional trends are observed. In Asia, there is a growing prevalence of NASH due to changing lifestyles and increasing obesity rates, driving the demand for treatment options. North America leads the market with a well-established healthcare infrastructure and extensive research activities focused on NASH treatment. In Europe, the market is driven by the presence of key pharmaceutical companies and a rising awareness about NASH among healthcare providers and patients. The Middle East and Africa region is witnessing a gradual increase in NASH cases, leading to a growing emphasis on early diagnosis and treatment. Latin America shows potential for market growth due to improving access to healthcare and rising investments in healthcare infrastructure for NASH management.
Global Non-Alcoholic Steatohepatitis Treatment Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Non-Alcoholic Steatohepatitis Treatment Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Global Non-Alcoholic Steatohepatitis Treatment Market - Industry Life Cycle |
3.4 Global Non-Alcoholic Steatohepatitis Treatment Market - Porter's Five Forces |
3.5 Global Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Global Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Global Non-Alcoholic Steatohepatitis Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Non-Alcoholic Steatohepatitis Treatment Market Trends |
6 Global Non-Alcoholic Steatohepatitis Treatment Market, 2021 - 2031 |
6.1 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Vitamin E and Pioglitazone, 2021 - 2031 |
6.1.3 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Obeticholic Acid (OCA), 2021 - 2031 |
6.1.4 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Lanifibranor, 2021 - 2031 |
6.1.5 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Semaglutide, 2021 - 2031 |
6.1.6 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Resmetirom, 2021 - 2031 |
6.1.7 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Aramchol, 2021 - 2031 |
6.1.8 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Cenicriviroc, 2021 - 2031 |
6.1.9 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Hospital Pharmacies, 2021 - 2031 |
6.2.3 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Retail and Specialty Pharmacies, 2021 - 2031 |
6.2.4 Global Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3.1 Overview & Analysis |
7 North America Non-Alcoholic Steatohepatitis Treatment Market, Overview & Analysis |
7.1 North America Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 - 2031 |
7.2 North America Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.4 North America Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
8 Latin America (LATAM) Non-Alcoholic Steatohepatitis Treatment Market, Overview & Analysis |
8.1 Latin America (LATAM) Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
8.4 Latin America (LATAM) Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
9 Asia Non-Alcoholic Steatohepatitis Treatment Market, Overview & Analysis |
9.1 Asia Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
9.4 Asia Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
10 Africa Non-Alcoholic Steatohepatitis Treatment Market, Overview & Analysis |
10.1 Africa Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
10.4 Africa Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
11 Europe Non-Alcoholic Steatohepatitis Treatment Market, Overview & Analysis |
11.1 Europe Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
11.4 Europe Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
12 Middle East Non-Alcoholic Steatohepatitis Treatment Market, Overview & Analysis |
12.1 Middle East Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
12.4 Middle East Non-Alcoholic Steatohepatitis Treatment Market, Revenues & Volume, By End-use, 2021 - 2031 |
13 Global Non-Alcoholic Steatohepatitis Treatment Market Key Performance Indicators |
14 Global Non-Alcoholic Steatohepatitis Treatment Market - Export/Import By Countries Assessment |
15 Global Non-Alcoholic Steatohepatitis Treatment Market - Opportunity Assessment |
15.1 Global Non-Alcoholic Steatohepatitis Treatment Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Non-Alcoholic Steatohepatitis Treatment Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
15.3 Global Non-Alcoholic Steatohepatitis Treatment Market Opportunity Assessment, By End-use, 2021 & 2031F |
16 Global Non-Alcoholic Steatohepatitis Treatment Market - Competitive Landscape |
16.1 Global Non-Alcoholic Steatohepatitis Treatment Market Revenue Share, By Companies, 2024 |
16.2 Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |